Sei Investments Co. Boosts Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Sei Investments Co. boosted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.0% in the second quarter, HoldingsChannel.com reports. The firm owned 59,211 shares of the medical instruments supplier’s stock after acquiring an additional 1,140 shares during the period. Sei Investments Co.’s holdings in LeMaitre Vascular were worth $4,872,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Shaker Investments LLC OH lifted its position in LeMaitre Vascular by 1.3% during the second quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock valued at $1,138,000 after acquiring an additional 175 shares during the last quarter. GAMMA Investing LLC increased its position in shares of LeMaitre Vascular by 57.0% during the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 199 shares in the last quarter. nVerses Capital LLC lifted its holdings in shares of LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 200 shares during the last quarter. Albion Financial Group UT boosted its position in shares of LeMaitre Vascular by 5.6% in the 1st quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock worth $264,000 after purchasing an additional 212 shares in the last quarter. Finally, Texas Permanent School Fund Corp grew its stake in LeMaitre Vascular by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock worth $1,151,000 after buying an additional 225 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Down 2.2 %

Shares of NASDAQ LMAT opened at $90.86 on Wednesday. LeMaitre Vascular, Inc. has a 52 week low of $44.27 and a 52 week high of $93.24. The business’s 50 day moving average price is $87.38 and its 200 day moving average price is $79.16. The firm has a market cap of $2.04 billion, a P/E ratio of 60.17, a P/E/G ratio of 2.41 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.37 earnings per share. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were issued a $0.16 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Analyst Ratings Changes

A number of equities research analysts have commented on LMAT shares. Barrington Research reiterated an “outperform” rating and issued a $92.00 price target on shares of LeMaitre Vascular in a research note on Friday, September 20th. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. JMP Securities boosted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Finally, Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target for the company. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.40.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 12,976 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the sale, the chief executive officer now owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO George W. Lemaitre sold 12,976 shares of the stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the transaction, the chief executive officer now owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The disclosure for this sale can be found here. Insiders have sold 43,251 shares of company stock worth $3,714,994 over the last quarter. 10.79% of the stock is currently owned by insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.